Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 15/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | PAH | P00439 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21638909 | 1.00 | HPRT1 (0.65) | HPRT1USP2CASP7HSD17B10NOS1 | |
| SCHEMBL9172629 | 0.86 | HPRT1 (0.69) | HPRT1 | |
| SCHEMBL7142937 | 0.85 | HPRT1 (0.64) | HPRT1USP2CASP7HSD17B10NOS1 | |
| SCHEMBL20509480 | 0.84 | HPRT1 (0.62) | HPRT1USP2CASP7HSD17B10NOS1 | |
| SCHEMBL10919055 | 0.83 | HPRT1 (0.58) | HPRT1USP2CASP7HSD17B10NOS1 | |
| SCHEMBL9685371 | 0.82 | HPRT1 (0.54) | HPRT1USP2CASP7HSD17B10NOS1 | |
| SCHEMBL9569709 | 0.81 | HPRT1 (0.59) | HPRT1USP2CASP7HSD17B10NOS1 | |
| SCHEMBL4713155 | 0.80 | HPRT1 (0.76) | HPRT1 | |
| SCHEMBL10919076 | 0.79 | HPRT1 (0.62) | HPRT1USP2CASP7HSD17B10NOS1 | |
| Phosphoric Acid SCHEMBL15054256 | 0.79 | HPRT1 (0.74) | HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200101091-A1 | ACYLNUCLEOSIDE PHOSPHONATES, PRODRUGS THEREOF AND USE THEREOF AS MEDICAMENT | ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER (FR) | 2020-04-02 | — | — | US | disclosed |
| EP-3601302-A1 | ACYLNUCLEOSIDE PHOSPHONATES, PRODRUGS THEREOF AND USE THEREOF AS MEDICAMENT | Université de Montpellier (FR) | 2020-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200101091-A1 | ACYLNUCLEOSIDE PHOSPHONATES, PRODRUGS THEREOF AND USE THEREOF AS MEDICAMENT | PNP, TYMP, PPA1 | HPRT1 23/4885USP2 4507/4885CASP7 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.